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Abstract
The case presented here illustrates a protothecal infection caused by Prototheca wickerhamii in a paediatric haematopoietic stem cell
recipient followed by a review of the literature of all 13 paediatric cases published since 1980. Protothecosis is a rare disease caused by
algae, not described in this setting before. Infection was proven additionally post-mortem from peritoneal dialysis fluid. Even though no
death of a paediatric patient due to this infection has been reported and the mortality rate associated with protothecosis is low, our patient
died from multiorgan failure as a result of numerous post-transplant complications and a strain of cultivated alga that was highly resistant to
antifungal agents. Prototheca spp. show various susceptibility profiles, and there is no direct correlation between in vitro activity and clinical
response. There are different treatment regimens described but there are no clear published guidelines of specific therapy of protothecosis.
Paediatric cases were successfully treated mostly with amphotericin B and azoles. As the number of immunocompromised patients
increases, it is necessary to think more about unusual pathogens such as Prototheca.
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Case Report
A 3-year-old boy with Philadelphia-chromosome-positive,
high-risk acute lymphoblastic leukaemia achieved the first
complete remission and underwent allogeneic stem cell
transplantation (SCT) from a 10/10 HLA-matched unrelated
donor. His conditioning regimen consisted of Fludarabine/
Treosulphan/Thiotepa and anti-thymocyte globulin + cyclo-
sporin A as a graft-versus-host disease (GVHD) prophylaxis.
The graft was infused after erythrodepletion due to ABO
incompatibility.
Day +1 after SCT he developed febrile neutropenia.
Aetiology of this febrile episode was later identified from a
blood culture as Klebsiella pneumoniae and it was treated
according to the antibiotic sensitivity tests. In the peri-trans-
plant period he developed a severe veno-occlusive liver
disease with high bilirubin blood level, body fluid retention
and ascites with the necessity for abdominal drain insertion.
Later, anuria and respiratory failure developed and the patient
was transferred to the intensive care unit for mechanical
ventilation and peritoneal dialysis. Bilirubin blood levels
continued to rise up to 857 lmol/L (50.1 mg/dL), a molecular
adsorbent recirculation system was used four times. On
neutrophil engraftment day +21 the patient’s condition had
improved—laboratory inflammation markers were decreased
as well as fever. On day +26, the intestinal form of GVHD
developed with massive intestinal bleeding. Candida fabianii and
multiresistant Staphylococcus epidermidis and Enterococcus fae-
calis were identified as microbial agents causing other
concomitant infections (Fig. 1).
Despite 39 days of peritoneal dialysis, the kidney function of
the patient did not improve and another febrile episode
developed with increased laboratory inflammation markers.
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Blood cultures and dialysate culture showed multiresistant
Stenotrophomonas maltophilia to be the cause of sepsis. Despite
intensive and multidisciplinary care the patient died on day +55
after SCT. In addition, the result of dialysate culture revealed a
very rare Prototheca wickerhamii. Autopsy was not performed.
Discussion
Prototheca spp. are ubiquitous chlorophyllous algae belonging
to the Chlorophyceae. Besides various environmental niches,
Prototheca spp. have been found colonizing the human skin,
fingernails and respiratory and digestive systems [1]. It is not a
common hospital-borne infection. Hospital-acquired cases
have been associated with surgery and orthopaedic proce-
dures, but human-to-human transmission has not been
reported [1]. The source of the infection in this case is
unknown.
Five species of Prototheca have been distinguished, of which
only two—P. wickerhamii and Prototheca zopfii—are described
as pathogenic in humans [1]. In the present case white and pale
cream-coloured yeast-like colonies were grown on Sabouraud
dextrose agar with antibiotics after 5 days of incubation at
30°C. Direct microscopy showed large Gram-positive cells of
various sizes resembling yeast-like formations but budding was
absent (Fig. 2). Further micromorphological and biochemical
description was made with identification of the strain as
P. wickerhamii.
According to animal experiments, Prototheca spp. seem to
have low virulence, overall their pathogenicity is moderate and
protothecosis is considered a rare opportunistic infection
[2,3].
FIG. 1. Course of present case with C reactive protein changes, microbiology findings and antifungal therapy.
(b)(a)
FIG. 2. Microscopic and cultivation results. (a) Direct microscopy of large cells resembling yeast-like formation without budding (9 200
magnification). (b) White and pale cream-coloured yeast-like colonies on Sabouraud dextrose agar.
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According to the clinical presentation, there are three
distinguished clinical forms known—cutaneous infection,
bursitis and systemic infection. The most common are
cutaneous infection and olecranon bursitis; systemic dissem-
ination or organ involvement represents only 10% of all
reported infections [4]. Previous review studies suggested a
2.2% attributable mortality rate, which represents a lower
number compared with candidaemia, but individual outcome
still depends on the history and clinical context of each patient
[5]. Among all patients with cancer and protothecosis, overall
mortality was 54% and attributable mortality was 14% [6].
Patients who are immunocompromised due to steroid use
or who have underlying haematological/solid malignancy or
AIDS have a higher risk of protothecosis.
More than 120 cases of protothecosis have been reported
and it is believed that a much greater number of cases are
unreported, perhaps because of morphological confusion with
other microbes such as Lacazia lobii, Coccidio desimmitis,
Histoplasma duboisii, Blastomyces dermatitis or Pneumocystis
jirovecii [7].
Protothecosis in children mostly presents as infections
involving various organs. From the 13 cases reported five were
cutaneous, with or without olecranon bursitis, one was a
catheter-related infection and the rest had other organ
involvement (Table 1). Generally, Prototheca spp. show various
susceptibility profiles, and there is no direct correlation
between in vitro activity and clinical response [1]. There are
no published guidelines of specific treatments for prototheco-
sis. Algae are susceptible to amphotericin B and most of them
were resistant to 5-flucytosine, fluconazole and itraconazole
[5]. In contrast to this, voriconazole shows superior activity
against P. wickerhamii [1]. In the case described here, the
P. wickerhamii strain was fully susceptible only to amphotericin
B, voriconazole was not effective (Table 2). Paediatric cases
were successfully treated mostly by amphotericin B and azoles
(Table 1). From review papers it can generally be concluded
that most failures are associated with monotherapy by azoles
[1]. The therapeutic response of paediatric patients to
amphotericin B treatment is very good, even though the
optimal dosage and duration of an antifungal therapy are
unknown. The only death of a child with protothecosis
reported is our present patient. Antifungal treatment and
prophylaxis of our patient followed the SCT guidelines using
micafungin antimycotic prophylaxis. Changes of anti-infective
agents followed the recommendations of the European Society
for Blood and Marrow Transplantation guidelines according to
the current clinical status and microbial finding in the patient
(Fig. 1). However, the anti-infective management was very
challenging because of the kidney failure and other post-trans-
plantation complications.
Protothecal infection usually runs with other co-pathogens
such as cytomegalovirus, herpes simplex virus, Staphyloccocus
aureus, Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella
pneumoniae, Escherichia coli, Cryptococcus spp., Candida glabrata
and Aspergillus spp. [1]. In the present case different co-patho-
gens were identified: Gram-negative bacterium Stenotropho-
monas maltophilia and Candida fabianii (Fig. 1).
Cytomegalovirus, Epstein–Barr virus, adenovirus and BK virus
infections repeatedly tested negative on PCR. Besides viruses,
mannan, anti-mannan and galactomannan antigen testing was
run for complete mycology follow up. Microbiological tests
were performed routinely every 3–4 days; collection of
specimens was performed in sterile conditions. Infection
developed on caspofungin, meropenem and acyclovir. Ampho-
tericin B appears to be the most effective drug for systemic
protothecosis, although it has been reported to be ineffective
in some cases. So far it is recommended as the first-line
therapy in cases of dissemination and for patients who are
severely immunocompromised, or have other underlying
illness [17]. This recommendation was irrelevant for our
patient because of the kidney failure that did not improve.
Duration of microbial identification in our settings is
approximately 4 days. The results of the cultures from the
peritoneal dialysate were obtained after the patient had died.
It is evident that the unstable and critical condition of the
patient played a key role in his death and the protothecal
infection was only a contributory factor. Regarding the source
of infection, the reported data of protothecosis in patients
with long-lasting peritoneal dialysis showed that the catheter
was infected. In the case described here, the peritoneal
catheter was replaced 1–2 days before death, due to its
malfunction and clogging with blood coagula. We have no
evidence of contaminated surgical equipment during the
handling procedure. Previous peritoneal dialysates tested
negative; this was the only positive specimen. After the
identification of P. wickerhamii, a sample of the alga was
deposited in the mycology laboratory archives.
According to published data, this is the first reported case
of protothecosis in a paediatric bone marrow transplantation
TABLE 2. Minimal inhibition concentration profile of Protot-
heca wickerhamii strain cultivated in the present case.
Antifungal agent Dosage (mg/L) Susceptibility
Voriconazole 32.0 Resistant
Posaconazole 2.0 Susceptible only
to higher dosage
Amphotericin B 0.094 Susceptible
Fluconazole 256.0 Resistant
Itraconazole 32.0 Resistant
Echinocandins (micafungin,
anidulafungin, caspofungin)
32.0 Resistant
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recipient. There is a rising probability of infection by less
common and more atypical infectious organisms. Prototheca is a
rare pathogen and so is not usually suspected. As the number
of immunocompromised patients increases, it is necessary to
think more of unusual pathogens when it comes to diagnosis of
infectious complications during treatment.
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